Net margin is calculated as Net Income divided by its Revenue. Intervacc AB's Net Income for the
three
months ended in Mar. 2026 was €-2.02 Mil. Intervacc AB's Revenue for the
three
months ended in Mar. 2026 was €0.31 Mil. Therefore, Intervacc AB's net margin for the quarter that ended in Mar. 2026 was -644.41%.
The historical rank and industry rank for Intervacc AB's Net Margin % or its related term are showing as below:
FRA:2E9'
s Net Margin % Range Over the Past 10 Years
Min: -1283.24 Med: -468.96 Max: -12.25
Current: -473.17
FRA:2E9's Net Margin % is ranked worse than 70.61% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:2E9: -473.17
Intervacc AB (FRA:2E9) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Intervacc AB Net Margin % Related Terms
Intervacc AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Intervacc AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a Net Margin % of -644.41% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #668 out of 946 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Intervacc AB's Net Margin % too high?
Intervacc AB's current Net Margin % is -644.41%. Based on the distribution chart, Intervacc AB ranks #668 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #668 out of 946 companies for Net Margin %. This places Intervacc AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Intervacc AB and its competitors. Intervacc AB's current Net Margin % is -644.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Net Margin % of -644.41%. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 12.2% above its estimated fair value. The current Net Margin % is -644.41%. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Net Margin % is -644.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.07 is trading 12.2% above its estimated GF Value™ of €0.06.
Key valuation signals for FRA:2E9:
Net Margin %: -644.41%
GF Value™: €0.06 vs. price of €0.07 (12.2% above fair value)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
